133 related articles for article (PubMed ID: 26859503)
1. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
[TBL] [Abstract][Full Text] [Related]
2. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
[TBL] [Abstract][Full Text] [Related]
3. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
[TBL] [Abstract][Full Text] [Related]
4. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
Mlakar DN; Bric TK; Škrjanec AL; Krajc M
Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
[TBL] [Abstract][Full Text] [Related]
5. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
[TBL] [Abstract][Full Text] [Related]
6. Impact of the bowel-screening programme on the diagnosis of colorectal cancer in Ayrshire and Arran.
Roxburgh CS; McTaggart F; Balsitis M; Diament RH
Colorectal Dis; 2013 Jan; 15(1):34-41. PubMed ID: 22632378
[TBL] [Abstract][Full Text] [Related]
7. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
[TBL] [Abstract][Full Text] [Related]
9. Early detection of colorectal cancer with faecal occult blood test screening.
Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
[TBL] [Abstract][Full Text] [Related]
10. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancers detected through screening are associated with lower stages and improved survival.
Lindebjerg J; Osler M; Bisgaard C
Dan Med J; 2014 Jan; 61(1):A4758. PubMed ID: 24393588
[TBL] [Abstract][Full Text] [Related]
12. Screen-detected colorectal cancers show improved cancer-specific survival when compared with cancers diagnosed via the 2-week suspected colorectal cancer referral guidelines.
Courtney ED; Chong D; Tighe R; Easterbrook JR; Stebbings WS; Hernon J
Colorectal Dis; 2013 Feb; 15(2):177-82. PubMed ID: 22709315
[TBL] [Abstract][Full Text] [Related]
13. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
[TBL] [Abstract][Full Text] [Related]
14. Colorectal adenocarcinomas diagnosed following a negative faecal immunochemical test show high-risk pathological features in a colon screening programme.
Steel MJ; Bukhari H; Gentile L; Telford J; Schaeffer DF
Histopathology; 2021 Apr; 78(5):710-716. PubMed ID: 33037645
[TBL] [Abstract][Full Text] [Related]
15. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme.
Gill MD; Bramble MG; Rees CJ; Lee TJ; Bradburn DM; Mills SJ
Br J Cancer; 2012 Jul; 107(3):417-21. PubMed ID: 22782347
[TBL] [Abstract][Full Text] [Related]
16. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
Van Roosbroeck S; Hoeck S; Van Hal G
Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
[TBL] [Abstract][Full Text] [Related]
17. Population-based screening improves histopathological prognostic factors in colorectal cancer.
Mengual-Ballester M; Pellicer-Franco E; Valero-Navarro G; Soria-Aledo V; García-Marín JA; Aguayo-Albasini JL
Int J Colorectal Dis; 2018 Jan; 33(1):23-28. PubMed ID: 29138933
[TBL] [Abstract][Full Text] [Related]
18. Introduction of a colorectal cancer screening programme: results from a single-centre study.
Vermeer NCA; Bahadoer RR; Bastiaannet E; Holman FA; Meershoek-Klein Kranenbarg E; Liefers GJ; van de Velde CJH; Peeters KCMJ
Colorectal Dis; 2018 Sep; 20(9):O239-O247. PubMed ID: 29917325
[TBL] [Abstract][Full Text] [Related]
19. Interval cancers after negative colonoscopy: population-based case-control study.
Brenner H; Chang-Claude J; Seiler CM; Hoffmeister M
Gut; 2012 Nov; 61(11):1576-82. PubMed ID: 22200840
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with colorectal cancer diagnosed in a randomized controlled trial of faecal occult blood screening.
Mapp TJ; Hardcastle JD; Moss SM; Robinson MH
Br J Surg; 1999 Oct; 86(10):1286-91. PubMed ID: 10540135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
